By Fineline Cube 
EndoCell Biotech, a Shanghai-based developer of regenerated islet technology, reportedly completed Series A and Pre-Series A+ financing rounds, raising a total of RMB 200 million (USD 27.7 million). The funding will support the advancement of the company’s first allogeneic universal regenerated pancreatic islet pipeline in China, enhance its strategic layout in Asia, and open new avenues for the treatment of diabetes and liver diseases.
Financing Rounds and Participants
The Series A funding was co-led by Shanghai Technology Venture Capital and Grand Neobay Ceyuan Fund, while the Pre-Series A+ round was led by Leo Group, with contributions from Panlin Capital and others.
Pipeline and Facility Development
EndoCell is focused on the in vitro reconstruction of human tissues and organs, specifically developing regenerative islets for transplantation to treat diabetes. The company has established a 4000 square meter “Organ and Tissue Reconstruction Center” in Shanghai Lingang New City. This facility includes the world’s first fully A-grade fully enclosed GMP production line for regenerating pancreatic islets, positioning EndoCell at the forefront of regenerative medicine.-Fineline Info & Tech